Taiwan Green Cross has long focused on prescription pharmaceuticals and plasma protein therapies, and is committed to introducing quality albumin products that provide stable therapeutic support for critically ill patients. As albumin is a valuable plasma-derived product, precision dosing, fluid balance management and reimbursement criteria are all critical in clinical practice — and the company works closely with front-line healthcare teams to support cross-specialty academic exchange.
Seminar sessions and focus
The Taiwan Green Cross team recently held albumin clinical application seminars at the intensive care unit of Ten-Chen General Hospital and the pharmacy department of Tainan Sin-Lau Hospital:
- Intensive care unit: The ICU is central to the treatment of critically ill patients with conditions such as sepsis, organ failure and severe hypoalbuminaemia. The seminar focused on the latest developments in albumin for fluid resuscitation, maintenance of colloid osmotic pressure and evidence-based treatment, supporting intensivists and nursing teams in determining optimal timing of administration.
- Hospital pharmacy teams: The pharmacy is the cornerstone of medication safety and pharmaceutical review. The team discussed with pharmacists the clinical literature on albumin, reimbursement criteria, and product manufacturing and quality management practices, so that rigorous pharmaceutical oversight can maximise the clinical benefit of this valuable medical resource.
Deepening cross-specialty collaboration
Taiwan Green Cross will continue to strengthen its partnerships with critical care medicine, hepatogastroenterology and pharmacy teams at healthcare institutions across Taiwan, regularly introducing the latest international evidence and clinical guidance on plasma protein therapies to support precision medicine and safeguard the health of critically ill patients.
About Taiwan Green Cross
Taiwan Green Cross focuses on prescription pharmaceuticals, medical devices and healthcare. We are committed to introducing and developing innovative medical technologies and products, offering clinical professionals and patients more complete treatment and care options, while actively expanding into international markets to advance the globalisation of Taiwan's healthcare industry.